Jun 29, 2019 7:00 am EDT Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
Jun 25, 2019 4:05 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 05, 2019 4:30 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun 04, 2019 9:36 am EDT Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Jun 01, 2019 9:00 am EDT Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2019 5:00 pm EDT Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors
May 15, 2019 5:05 pm EDT Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2019 8:30 am EDT Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
May 09, 2019 8:00 am EDT Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress